Activation of extracellular signal-regulated kinase is critical for the discriminative stimulus effects induced by U-50,488H

Synapse

Volumn 65, Issue 10, 2011, Pages 1052-1061

  Yoshizawa, Kazumi ^a   Narita, Minoru ^a   Saeki, Mai ^a   Narita, Michiko ^a   Isotani, Kana ^a   Horiuchi, Hiroshi ^a   Imai, Satoshi ^a   Kuzumaki, Naoko ^a   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Drug discrimination; Extracellular signal regulated kinase; U 50,488H

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG DOSE COMPARISON; DRUG EFFECT; GENE EXPRESSION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; AMYGDALA; ANALGESICS, NON-NARCOTIC; ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISCRIMINATION LEARNING; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; NUCLEUS ACCUMBENS; PHOSPHORYLATION; RATS; RATS, INBRED F344;

EID: 79960958495     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20937     Document Type: Article

References (24)

1. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. 1984. Endogenous opioids: Biology and function. Annu Rev Neurosci 7: 223-255.
2. Bals-Kubik R, Herz A, Shippenberg TS. 1989. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology (Berl) 98: 203-206.
3. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. 1993. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264: 489-495.
4. Baxter MG, Murray EA. 2002. The amygdala and reward. Nat Rev Neurosci 3: 563-573.
5. Belcheva MM, Clark AL, Hass PD, Serna JS, Hahn JW, Kiss A, Cosia C. 2005. Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 280: 27662-27669.
6. Bruchas MR, Macey TA, Lowe JD, Chavkin C. 2006. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281: 18081-18089.
7. Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, Chavkin C. 2007. Stress- induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 27: 11614-11623.
8. DiNieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, Neve RL, Nestler EJ, Carlezon WAJr. 2009. Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci 29: 1855-1859.
9. Fraser HF, Rosenberg DE. 1964. Studies on the human addiction liability of 2'-hydroxy-5-9-dimethyl-2-(3, 3-dimethylallyl)-6, 7-benzomorphan (WIN 20, 228): A weak narcotic antagonist. J Pharmacol Exp Ther 143: 149-156.
10. Funada M, Suzuki T, Narita M, Misawa M, Nagase H. 1993. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32: 1315-1323.
11. Lisman J, Schulman H, Cline H. 2002. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 3: 175-190.
12. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. 1987. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 7: 2445-2464.
13. Mori T, Nomura M, Yoshizawa K, Nagase H, Narita M, Suzuki T. 2004. Differential properties between TRK-820 and U-50, 488H, 488H on the discriminative stimulus effects in rats. Life Sci 75: 2473-2482.
14. Mori T, Nomura M, Yoshizawa K, Nagase H, Sawaguchi T, Narita M, Suzuki T. 2006. Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists U-50, 488H, but not TRK-820 in rats. J Pharmacol Sci 100: 157-161.
15. Narita M, Takahashi Y, Takamori K, Funada M, Suzuki T, Misawa M, Nagase H. 1993. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice. Jpn J Pharmacol 62: 15-24.
16. Nestler EJ, Carlezon WAJr. 2006. The mesolombic dopamine reward circuit in depression. Biol Psychiatry 59: 1151-1159.
17. Pfeiffer A, Brantl V, Herz A, Emrich HM. 1986. Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776.
18. Spanagel R, Herz A, Shippenberg TS. 1990. The effects of opioid peptides on dopamine release in the nucleus accumbens: An invivo microdialysis study. J Neurochem 55: 1734-1740.
19. Suzuki T, Shiozaki Y, Masukawa Y, Misawa M, Nagase H. 1992. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58: 435-442.
20. Teal JJ, Holtzman SG. 1980. Discriminative stimulus effects of prototype opiate receptor agonists in monkeys. Eur J Pharmacol 68: 1-10.
21. Thomas GM, Huganir RL. 2004. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5: 173-183.
22. White JM, Holtzman SG. 1983. Further characterization of the three-choice morphine, cyclazocine and saline discrimination paradigm: Opioids with agonist and antagonist properties. J Pharmacol Exp Ther 224: 95-99.
23. Wise RA. 2004. Dopamine, learning and motivation. Nat Rev Neurosci 5: 483-494.
24. Yoshizawa K, Narita M, Mori T, Miyatake M, Isotani K, Tomiyasu S, Tsukiyama Y, Suzuki T. Role of dopamine D2 and D3 receptors in mediating the U-50, 488H discriminative cue: Comparison with methamphetamine and cocaine. Addict Biol (in press).